Glucagon-like peptide 2 and its beneficial effects on gut function and health in production animals

Domestic Animal Endocrinology

Volumn 56, Issue , 2016, Pages S56-S65

  Connor, E E ^a   Evock Clover, C M ^a   Wall, E H ^b   Baldwin, R L ^a   Santin Duran, M ^a   Elsasser, T H ^a   Bravo, D M ^b  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

^b Pancosma   (Switzerland)

Author keywords

Glucagon like peptide 2; Gut health; Intestinal barrier function; Protozoan infection

Indexed keywords

GLUCAGON LIKE PEPTIDE 2;

ANIMAL; ANIMAL PARASITOSIS; BOVINE; CATTLE DISEASE; DRUG EFFECTS; GASTROINTESTINAL TRACT; HUMAN; LIVESTOCK; PARASITOLOGY; PHYSIOLOGY;

ANIMALS; CATTLE; CATTLE DISEASES; GASTROINTESTINAL TRACT; GLUCAGON-LIKE PEPTIDE 2; HUMANS; LIVESTOCK; PROTOZOAN INFECTIONS, ANIMAL;

EID: 84979884891     PISSN: 07397240     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.domaniend.2015.11.008     Document Type: Review

References (118)

1. [1] Kim, W., Egan, J.M., The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 60 (2008), 470–512.
2. [2] Moran-Ramos, S., Tovar, A.R., Torres, N., Diet: friend or foe of enteroendocrine cells–how it interacts with enteroendocrine cells. Adv Nutr 3 (2012), 8–20.
3. [3] Diakogiannaki, E., Gribble, F.M., Reimann, F., Nutrient detection by incretin hormone secreting cells. Physiol Behav 106 (2012), 387–393.
4. [4] Gribble, F.M., The gut endocrine system as a coordinator of postprandial nutrient homoeostasis. Proc Nutr Soc 71 (2012), 456–462.
5. [5] Mace, O.J., Marshall, F., Digestive physiology of the pig symposium: gut chemosensing and the regulation of nutrient absorption and energy supply. J Anim Sci 91 (2013), 1932–1945.
6. [6] Cuomo, R., D'Alessandro, A., Andreozzi, P., Vozzella, L., Sarnelli, G., Gastrointestinal regulation of food intake: do gut motility, enteric nerves and entero-hormones play together?. Minerva Endocrinol 36 (2011), 281–293.
7. [7] Holzer, P., Reichmann, F., Farzi, A., Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. Neuropeptides 46 (2012), 261–274.
8. [8] Nadkarni, P., Chepurny, O.G., Holz, G.G., Regulation of glucose homeostasis by GLP-1. Prog Mol Biol Transl Sci 121 (2014), 23–65.
9. [9] Wong, I.P.L., Baldock, P.A., Herzog, H., Gastrointestinal peptides and bone health. Curr Opin Endocrinol Diabetes Obes 17 (2010), 44–50.
10. [10] El-Jamal, N., Erdual, E., Neunlist, M., Koriche, D., Dubuquoy, C., Maggiotto, F., Chevalier, J., Berrebi, D., Dubuquoy, L., Boulanger, E., Cortot, A., Desreumaux, P., Glugacon-like peptide-2: broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration. Am J Physiol Gastrointest Liver Physiol 307 (2014), G274–G285.
11. [11] Arda-Pirinccia, P., Oztay, F., Bayrak, B.B., Yanardag, R., Bolkent, S., Teduglutide, a glucagon-like peptide 2 analogue: a novel protective agent with anti-apoptotic and anti-oxidant properties in mice with lung injury. Peptides 38 (2012), 238–247.
12. [12] Guan, X., The CNS glucagon-like peptide-2 receptor in the control of energy balance and glucose homeostasis. Am J Physiol Regul Integr Comp Physiol 307 (2014), R585–R596.
13. [13] Iwai, T., Jin, K., Ohnuki, T., Sasaki-Hamada, S., Nakamura, M., Saitoh, A., Sugiyama, A., Ikeda, M., Tanabe, M., Oka, J.I., Glucagon-like peptide-2-induced memory improvement and anxiolytic effects in mice. Neuropeptides 49 (2015), 7–14.
14. [14] Sasaki-Hamada, S., Yuri, Y., Hoshi, M., Oka, J.I., Immunohistochemical determination of the site of antidepressant-like effects of glucagon-like peptide-2 in ACTH-treated mice. Neuroscience 294 (2015), 156–165.
15. [15] Dhillo, W.S., Bloom, S.R., Gastrointestinal hormones and regulation of food intake. Horm Metab Res 36 (2004), 846–851.
16. [16] Murphy, K.G., Dhillo, W.S., Bloom, S.R., Gut peptides in the regulation of food intake and energy homeostasis. Endocr Rev 27 (2006), 719–727.
17. [17] Karra, E., Batterham, R.L., The role of gut hormones in the regulation of body weight and energy homeostasis. Mol Cell Endocrinol 316 (2010), 120–128.
18. [18] Wallis, K., Walters, J.R.F., Forbes, A., Review article: glucagon-like peptide 2—current applications and future directions. Aliment Ther 25 (2007), 365–372.
19. [19] Harrison, E., Lal, S., McLaughlin, J.T., Enteroendocrine cells in gastrointestinal pathophysiology. Curr Opin Pharmacol 13 (2013), 941–945.
20. [20] Wu, T., Rayner, C.K., Young, R.L., Horowitz, M., Gut motility and enteroendocrine secretion. Curr Opin Pharmacol 13 (2013), 928–934.
21. [21] Tappenden, K.A., Albin, D.M., Bartholome, A.L., Mangian, H.F., Glucagon-like peptide-2 and short-chain fatty acids: a new twist to an old story. J Nutr 133 (2003), 3717–3720.
22. [22] Burrin, D.G., Stoll, B., Guan, X., Glucagon-like peptide 2 function in domestic animals. Domest Anim Endocrinol 24 (2003), 103–122.
23. [23] Burrin, D., Stoll, B., Moore, D., Digestive physiology of the pig symposium: intestinal bile acid sensing is linked to key endocrine and metabolic signaling pathways. J Anim Sci 91 (2013), 1991–2000.
24. [24] Moran, A.W., Al-Rammahi, M.A., Arora, D.K., Batchelor, D.J., Coulter, E.A., Ionescu, C., Bravo, D., Shirazi-Beechey, S.P., Expression of Na1/glucose co-transporter 1 (SGLT1) is enhanced by supplementation of the diet of weaning piglets with artificial sweeteners. Br J Nutr 104 (2010), 647–655.
25. [25] Moran, A.W., Al-Rammahi, M., Zhang, C., Bravo, D., Calsamiglia, S., Shirazi-Beechey, S.P., Sweet taste receptor expression in ruminant intestine and its activation by artificial sweeteners to regulate glucose absorption. J Dairy Sci 97 (2014), 4955–4972.
26. [26] Ipharraguerre, I.R., Tedó, G., Menoyo, D., de Diego Cabero, N., Holst, J.J., Nofrarías, M., Mereu, A., Burrin, D.G., Bile acids induce glucagon-like peptide 2 secretion with limited effects on intestinal adaptation in early weaned pigs. J Nutr 143 (2013), 1899–1905.
27. [27] Baldassano, S., Amato, A., GLP-2: what do we know? What are we going to discover?. Regul Pept 194–195 (2014), 6–10.
28. [28] Drucker, D.J., Yusta, B., Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol 76 (2014), 561–583.
29. [29] Kissow, H., Glucagon-like peptides 1 and 2: intestinal hormones implicated in the pathophysiology of mucositis. Curr Opin Support Palliat Care 9 (2015), 196–202.
30. [30] Connor, E.E., Evock-Clover, C.M., Walker, M.P., Elsasser, T.H., Kahl, S., Comparative gut physiology symposium: comparative physiology of glucagon-like peptide-2: implications and applications for production and health of ruminants. J Anim Sci 93 (2015), 492–501.
31. [31] Dubé, P.E., Brubaker, P.L., Nutrient, neural and endocrine control of glucagon-like peptide secretion. Horm Metab Res 36 (2004), 755–760.
32. [32] Mojsov, S., Heinrich, G., Wilson, I.B., Ravazzola, M., Orci, L., Habener, J.F., Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261 (1986), 11880–11889.
33. [33] Drucker, D.J., Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 1 (2005), 22–31.
34. [34] Drucker, D.J., Brubaker, P.L., Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine. Proc Natl Acad Sci U S A 86 (1989), 3953–3957.
35. [35] Hill, M.E., Asa, S.L., Drucker, D.J., Essential requirement for Pax6 in control of enteroendocrine proglucagon gene transcription. Mol Endocrinol 13 (1999), 1474–1486.
36. [36] Trinh, D.K.Y., Zhang, K., Hossain, M., Brubaker, P.L., Drucker, D.J., Pax-6 activates endogenous proglucagon gene expression in the rodent gastrointestinal epithelium. Diabetes 52 (2003), 425–433.
37. [37] Yi, F., Brubaker, P.L., Jin, T., TCF-4 mediates cell type-specific regulation of proglucagon gene expression by β-catenin and glycogen synthase kinase-3β. J Biol Chem 280 (2005), 1457–1464.
38. [38] Jin, T., Mechanisms underlying proglucagon gene expression. J Endocrinol 198 (2008), 17–28.
39. [39] Hoyt, E.C., Lund, P.K., Winesett, D.E., Fuller, C.R., Ghatei, M.A., Bloom, S.R., Ulshen, M.H., Effects of fasting, refeeding, and intraluminal triglyceride on proglucagon expression in jejunum and ileum. Diabetes 45 (1996), 434–439.
40. [40] Drucker, D.J., Shi, Q., Crivici, A., Sumner-Smith, M., Tavares, W., Hill, M., DeForest, L., Cooper, S., Brubaker, P.L., Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol 15 (1997), 673–677.
41. [41] Munroe, D.G., Gupta, A.K., Kooshesh, F., Vyas, T.B., Rizkalla, G., Wang, H., Demchyshyn, L., Yang, Z.J., Kamboj, R.K., Chen, H., McCallum, K., Sumner-Smith, M., Drucker, D.J., Crivici, A., Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci U S A 96 (1999), 1569–1573.
42. [42] Tavares, W., Drucker, D.J., Brubaker, P.L., Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. Am J Physiol Endocrinol Metab 278 (2000), E134–E139.
43. [43] Thulesen, J., Knudsen, L.B., Hartmann, B., Hastrup, S., Kissow, H., Jeppesen, P.B., Ørskov, C., Holst, J.J., Poulsen, S.S., The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist. Regul Pept 103 (2002), 9–15.
44. [44] Hartmann, B., Harr, M.B., Jeppesen, P.B., Wojdemann, M., Deacon, C.F., Mortensen, P.B., Holst, J.J., In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 85 (2000), 2884–2888.
45. [45] Hartmann, B., Thulesen, J., Kissow, H., Thulesen, S., Orskov, C., Ropke, C., Poulsen, S.S., Holst, J.J., Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology 141 (2000), 4013–4020.
46. [46] Yazbeck, R., Howarth, G.S., Abbott, C.A., Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward?. Cytokine Growth Factor Rev 20 (2009), 175–184.
47. [47] Inoue, T., Higashiyama, M., Kaji, I., Rudenkyy, S., Higuchi, K., Guth, P.H., Engel, E., Kaunitz, J.D., Akiba, Y., Dipeptidyl peptidase IV inhibition prevents the formation and promotes the healing of indomethacin-induced intestinal ulcers in rats. Dig Dis Sci 59 (2014), 1286–1295.
48. [48] Marier, J.F., Mouksassi, M.S., Gosselin, N.H., Beliveau, M., Cyran, J., Wallens, J., Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease. J Clin Pharmacol 50 (2010), 36–49.
49. [49] Alters, S.E., McLaughlin, B., Spink, B., Lachinyan, T., Wang, C.W., Podust, V., Schellenberger, V., Stemmer, W.P., GLP2–2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model. PLoS One, 7, 2012, e50630.
50. [50] Podust, V.N., Sim, B.C., Kothari, D., Henthorn, L., Gu, C., Wang, C.W., McLaughlin, B., Schellenberger, V., Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer. Protein Eng Des Sel 26 (2013), 743–753.
51. [51] Qi, K.K., Wu, J., Deng, B., Li, Y.M., Xu, Z.W., PEGylated porcine glucagon-like peptide-2 improved the intestinal digestive function and prevented inflammation of weaning piglets challenged with LPS. Animal 12 (2015), 1–9.
52. [52] Furness, J.B., Rivera, L.R., Cho, H.-J., Bravo, D.M., Callaghan, B., The gut as a sensory organ. Nat Rev Gastroenterol Hepatol 10 (2013), 729–740.
53. [53] Brubaker, P.L., Anini, Y., Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can J Physiol Pharmacol 81 (2003), 1005–1012.
54. [54] Lim, G.E., Brubaker, P.L., Glucagon-like peptide 1 secretion by the L-cell: the view from within. Diabetes 55:Suppl. 2 (2006), S70–S77.
55. [55] Shirazi-Beechey, S.P., Moran, A.W., Bravo, D., Al-Rammahi, M., Nonruminant nutrition symposium: intestinal glucose sensing and regulation of glucose absorption: implications for swine nutrition. J Anim Sci 89 (2011), 1854–1862.
56. [56] Shirazi-Beechey, S.P., Daly, K., Al-Rammahi, M., Moran, A.W., Bravo, D., Role of nutrient-sensing taste 1 receptor (T1R) family members in gastrointestinal chemosensing. Br J Nutr 111:Suppl 1 (2014), S8–S15.
57. [57] Akiba, Y., Kaunitz, J.D., Duodenal luminal chemosensing; acid, ATP, and nutrients. Curr Pharm Des 20 (2014), 2760–2765.
58. [58] Rowland, K.J., Brubaker, P.L., The “cryptic” mechanism of action of glucagon-like peptide-2. Am J Physiol Gastrointest Liver Physiol 301 (2011), G1–G8.
59. [59] Thymann, T., Le Huërou-Luron, I., Petersen, Y.M., Hedemann, M.S., Elinf, J., Jensen, B.B., Holst, J.J., Hartmann, B., Sangild, P.T., Glucagon-like peptide 2 treatment may improve intestinal adaptation during weaning. J Anim Sci 92 (2014), 2070–2079.
60. [60] Ørskov, C., Hartmann, B., Poulsen, S.S., Thulesen, J., Hare, K.J., Holst, J.J., GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept 124 (2005), 105–112.
61. [61] Guan, X., Karpen, H.E., Stephens, J., Bukowski, J.T., Niu, S., Zhang, G., Stoll, B., Finegold, M.J., Holst, J.J., Hadsell, D.L., Nichols, B.L., Burrin, D.G., GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 130 (2006), 150–164.
62. [62] Nelson, D.W., Sharp, J.W., Brownfield, M.S., Raybould, H.E., Ney, D.M., Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat. Endocrinology 148 (2007), 1954–1962.
63. [63] Dubé, P.E., Forse, C.L., Bahrami, J., Brubaker, P.L., The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology 131 (2006), 589–605.
64. [64] Bjerknes, M., Cheng, H., Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci U S A 98 (2001), 12497–12502.
65. [65] Anini, Y., Izzo, A., Oudit, G.Y., Backx, P.H., Brubaker, P.L., Role of phosphatidylinositol-3 kinase-gamma in the actions of glucagon-like peptide-2 on the murine small intestine. Am J Physiol Endocrinol Metab 292 (2007), E1599–E1606.
66. [66] Guan, X., Stoll, B., Lu, X., Tappenden, K.A., Holst, J.J., Hartmann, B., Burrin, D.G., GLP-2–mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide–dependent in TPN-fed piglets. Gastroenterology 125 (2003), 136–147.
67. [67] Sigalet, D.L., Wallace, L.E., Holst, J.J., Martin, G.R., Kaji, T., Tanaka, H., Sharkey, K.A., Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Amer J Physiol Gastrointest Liver Physiol 293 (2007), G211–G221.
68. [68] Sigalet, D.L., Wallace, L., De Heuval, E., Sharkey, K.A., The effects of glucagon-like peptide 2 on enteric neurons in intestinal inflammation. Neurogastroenterol Motil, 22, 2010 1318-e350.
69. [69] de Heuvel, E., Wallace, L., Sharkey, K.A., Sigalet, D.L., Glucagon-like peptide 2 induces vasoactive intestinal polypeptide expression in enteric neurons via phophatidylinositol 3-kinase-ɣ signaling. Am J Physiol Endocrinol Metab 303 (2012), E994–E1005.
70. [70] Yusta, B., Holland, D., Waschek, J.A., Drucker, D.J., Intestinotrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in mice. Endocrinology 153 (2012), 2623–2632.
71. [71] Arda-Pirincci, P., Bolkent, S., The role of glucagon-like peptide-2 on apoptosis, cell proliferation, and oxidant–antioxidant system at a mouse model of intestinal injury induced by tumor necrosis factor-alpha/actinomycin D. Mol Cell Biochem 350 (2011), 13–27.
72. [72] Zhang, W., Zhu, W., Zhang, J., Li, N., Li, J., Protective effects of glucagon-like peptide 2 on intestinal ischemia-reperfusion rats. Microsurgery 28 (2008), 285–290.
73. [73] Lee, S.-J., Lee, J., Li, K.K., Holland, D., Maughan, H., Guttman, D.S., Yusta, B., Drucker, D.J., Disruption of the murine Glp2r impairs paneth cell function and increases susceptibility to small bowel enteritis. Endocrinology 153 (2012), 1141–1151.
74. [74] Clevers, H.C., Bevins, C.L., Paneth cells: maestros of the small intestinal crypts. Annu Rev Physiol 75 (2013), 289–311.
75. [75] Peterson, L.W., Artis, D., Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol 14 (2014), 141–153.
76. [76] Chen, J., Dong, J.T., Li, X.J., Gu, Y., Cheng, Z.J., Cai, Y.K., Glucagon-like peptide-2 protects impaired intestinal mucosal barriers in obstructive jaundice rats. World J Gastroenterol 21 (2015), 484–490.
77. [77] Benjamin, M.A., McKay, D.M., Yang, P.-C., Cameron, H., Perdue, M.H., Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 47 (2000), 112–119.
78. [78] Caricilli, A.M., Castoldi, A., Olsen, N., Câmara, S., Intestinal barrier: a gentlemen's agreement between microbiota and immunity. World J Gastrointest Pathophysiol 5 (2014), 18–32.
79. [79] Cani, P.D., Possemiers, S., Van de Wiele, T., Guiot, Y., Everard, A., Rottier, O., Geurts, L., Naslain, D., Neyrinck, A., Lambert, D.M., Muccioli, G.G., Delzenne, N.M., Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58 (2009), 1091–1103.
80. [80] Dong, C.X., Zhao, W., Solomon, C., Rowland, K.J., Ackerley, C., Robine, S., Holzenberger, M., Gonska, T., Brubaker, P.L., The intestinal epithelial insulin-like growth factor-1 receptor links glucagon-like peptide-2 action to gut barrier function. Endocrinology 155 (2014), 370–379.
81. [81] de Heer, J., Pedersen, J., Orskov, C., Holst, J.J., The α cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas. Diabetologia 50 (2007), 2135–2142.
82. [82] Bahrami, J., Longuet, C., Baggio, L.L., Li, K., Drucker, D.J., The glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse. Gastroenterology 139 (2010), 857–868.
83. [83] Baldassano, S., Rappa, F., Amato, A., Cappello, F., Mulè, F., GLP-2 as beneficial factor in the glucose homeostasis in mice fed a high fat diet. J Cell Physiol 230 (2015), 3029–3036.
84. [84] Honda, K., Saneyasu, T., Shimatani, T., Aoki, K., Yamaguchi, T., Nakanishi, K., Kamisoyama, H., Intracerebroventricular administration of chicken glucagon-like peptide-2 potently suppresses food intake in chicks. Anim Sci J 86 (2015), 312–318.
85. [85] Iwai, T., Kaneko, M., Sasaki-Hamada, S., Oka, J.I., Characterization of the hypotensive effects of glucagon-like peptide-2 in anesthetized rats. Neurosci Lett 550 (2013), 104–108.
86. [86] Walsh, J.S., Henriksen, D.B., Feeding and bone. Arch Biochem Biophys 503 (2010), 11–19.
87. [87] Taylor-Edwards, C.C., Burrin, D.G., Holst, J.J., McLeod, K.R., Harmon, D.L., Glucagon-like peptide-2 (GLP-2) increases small intestinal blood flow and mucosal growth in ruminating calves. J Dairy Sci 94 (2011), 888–898.
88. [88] Taylor-Edwards, C.C., Burrin, D.G., Kristensen, N.B., Holst, J.J., McLeod, K.R., Harmon, D.L., Glucagon-like peptide-2 (GLP-2) increases net amino acid utilization by the portal-drained viscera of ruminating calves. Animal 6 (2012), 1985–1997.
89. [89] Connor, E.E., Kahl, S., Elsasser, T.H., Baldwin, R.L. VI, Fayer, R., Santin-Duran, M., Sample, G.L., Evock-Clover, C.M., Glucagon-like peptide 2 therapy reduces negative effects of diarrhea on calf gut. J Dairy Sci 96 (2013), 1793–1802.
90. [90] Siurana, A., Wall, E.H., Rodriguez, M., Castillejos, L., Ferret, A., Calsamiglia, S., The effect of dietary supplementation of artificial sweetener on performance of milk-fed calves. J Dairy Sci, 97(Suppl. 1), 2014, 810 Abstract 1655.
91. [91] Wall, E.H., Bravo, D.M., Supplementation with artificial sweetener improves milk yield and composition and alters nutrient partitioning in lactating dairy cows. J Dairy Sci, 98(Suppl. 2), 2015, 464 Abstract T431.
92. [92] McMeniman, J.P., Rivera, J.D., Schlegel, P., Rounds, W., Galyean, M.L., Effects of an artificial sweetener on health, performance, and dietary preference of feedlot cattle. J Anim Sci 84 (2006), 2491–2500.
93. [93] Ponce, C.H., Brown, M.S., Silva, J.S., Schlegel, P., Rounds, W., Hallford, D.M., Effects of a dietary sweetener on growth performance and health of stressed beef calves and on diet digestibility and plasma urinary metabolite concentrations of healthy calves. J Anim Sci 92 (2014), 1630–1638.
94. [94] Burrin, D.G., Stoll, B., Guan, X., Cui, L., Chang, X., Holst, J.J., Glucagon-like peptide 2 dose-dependently activates intestinal cell survival and proliferation in neonatal pigs. Endocrinology 146 (2005), 22–32.
95. [95] Sigalet, D.L., de Heuvel, E., Wallace, L., Bullock, E., Turner, J., Wales, P.W., Nation, P., Wizzard, P.R., Hartmann, B., Assad, M., Holst, J.J., Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs. Regul Pept 188 (2014), 70–80.
96. [96] Sterk, A., Schlegel, P., Mul, A.J., Ubbink-Blanksma, M., Bruininx, E.M., Effects of sweeteners on individual feed intake characteristics and performance in group-housed weanling pigs. J Anim Sci 86 (2008), 2990–2997.
97. [97] Hu, X.F., Guo, Y.M., Huang, B.Y., Bun, S., Zhang, L.B., Li, J.H., Liu, D., Long, F.Y., Yang, X., Jiao, P., The effect of glucagon-like peptide 2 injection on performance, small intestinal morphology, and nutrient transporter expression of stressed broiler chickens. Poult Sci 89 (2010), 1967–1974.
98. [98] St.-Pierre, N.R., Cobanov, B., Schnitkey, G., Economic losses from heat stress by US livestock industries. J Dairy Sci 86:Suppl. (2003), E52–E77.
99. [99] Pearce, S.C., Venkatesh, M., Boddicker, R.L., Johnson, J.S., Weber, T.E., Ross, J.W., Rhoads, R.P., Baumgard, L.H., Gabler, N.K., Heat stress reduces intestinal barrier integrity and favors intestinal glucose transport in growing pigs. PLoS One, 8, 2013, e70215.
100. [100] Wang, J.-H., Inoue, T., Higashiyama, M., Guth, P.H., Engel, E., Kaunitz, J.D., Akiba, Y., Umami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats. J Pharmacol Exp Ther 339 (2011), 464–473.
101. [101] Bauchart-Thevret, C., Stoll, B., Benight, N.M., Olutoye, O., Lazar, D., Burrin, D.G., Supplementing monosodium glutamate to partial enteral nutrition slows gastric emptying in preterm pigs. J Nutr 143 (2013), 563–570.
102. [102] Pi, D., Liu, Y., Shi, H., Li, S., Odle, J., Lin, X., Zhu, H., Chen, F., Hou, Y., Leng, W., Dietary supplementation of aspartate enhances intestinal integrity and energy status in weanling piglets after lipopolysaccharide challenge. J Nutr Biochem 25 (2014), 456–462.
103. [103] Liu, Y., Chen, F., Odle, J., Lin, X., Jacobi, S.K., Zhu, H., Wu, Z., Hou, Y., Fish oil enhances intestinal integrity and inhibits TLR4 and NOD2 signaling pathways in weaned pigs after LPS challenge. J Nutr 142 (2012), 2017–2024.
104. [104] Walker, M.P., Evock-Clover, C.M., Elsasser, T.H., Connor, E.E., Short communication: glucagon-like peptide-2 and coccidiosis alter tight junction gene expression in gastrointestinal tract of dairy calves. J Dairy Sci 98 (2015), 3432–3437.
105. [105] Yu, C., Jia, G., Jiang, Y., Deng, Q., Chen, Z., Xu, Z., Chen, X., Wang, K., Effect of glucagon-like peptide 2 on tight junction in jejunal epithelium of weaned pigs though MAPK signaling pathway. Asian Australas J Anim Sci 27 (2014), 733–742.
106. [106] Qi, K.K., Wu, J., Xu, Z.W., Effects of PEGylated porcine glucagon-like peptide-2 therapy in weaning piglets challenged with lipopolysaccharide. Peptides 58 (2014), 7–13.
107. [107] Livesey, C., Payne, J., Diagnosis and investigation of fluorosis in livestock and horses. In Pract 33 (2011), 454–461.
108. [108] Simon, M.J., Beil, F.T., Rüther, W., Busse, B., Koehne, T., Steiner, M., Pogoda, P., Ignatius, A., Amling, M., Oheim, R., High fluoride and low calcium levels in drinking water is associated with low bone mass, reduced bone quality and fragility fractures in sheep. Osteoporos Int 25 (2014), 1891–1903.
109. [109] Leng, W., Liu, Y., Shi, H., Li, S., Zhu, H., Pi, D., Hou, Y., Gong, J., Aspartate alleviates injury and regulates mRNA expressions of TLR4 and NOD signaling-related genes in weaned pigs after lipopolysaccharide challenge. J Nutr Biochem 25 (2014), 592–599.
110. [110] Singh, K., Ritchey, J.W., Confer, A.W., Mannheimia haemolytica: bacterial–host interactions in bovine pneumonia. Vet Pathol 48 (2011), 338–348.
111. [111] Anderson, B.C., Cryptosporidiosis in bovine and human health. J Dairy Sci 81 (1998), 3036–3041.
112. [112] Klein, P., Kleinová, T., Volek, Z., Šimůnek, J., Effect of Cryptosporidium parvum infection on the absorptive capacity and paracellular permeability of the small intestine in neonatal calves. Vet Parasitol 152 (2008), 53–59.
113. [113] Chalmers, R.M., Davies, A.P., Minireview: clinical cryptosporidiosis. Exp Parasitol 124 (2010), 138–146.
114. [114] Yusta, B., Somwar, R., Wang, F., Munroe, D., Grinstein, S., Klip, A., Drucker, D.J., Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor. J Biol Chem 274 (1999), 30459–30467.
115. [115] Ubelmann, F., Chamaillard, M., El-Marjou, F., Simon, A., Netter, J., Vignjevic, D., Nichols, B.L., Quezada-Calvillo, R., Grandjean, T., Louvard, D., Revenu, C., Robine, S., Enterocyte loss of polarity and gut wound healing rely upon the F-actin-severing function of villin. Proc Natl Acad Sci U S A 110 (2013), E1380–1389.
116. [116] Deng, M., Rutherford, M.S., Abrahamsen, M.S., Host intestinal epithelial response to Cryptosporidium parvum. Adv Drug Deliv Rev 56 (2004), 869–884.
117. [117] Chen, X.M., O'Hara, S.P., Huang, B.Q., Splinter, P.L., Nelson, J.B., LaRusso, N.F., Localized glucose and water influx facilitates Cryptosporidium parvum cellular invasion by means of modulation of host-cell membrane protrusion. Proc Natl Acad Sci U S A 102 (2005), 6338–6343.
118. [118] Savidge, T.C., Shmakov, A.N., Walker-Smith, J.A., Phillips, A.D., Chapter 11: Intestinal proliferation and infection in childhood. Page 111 Halter, F., Winton, D., Wright, N.A., (eds.) The gut as a model in cell and molecular biology, 1997, Kluwer Academic Publishers, Hingham, MA.